New Drug: Zenocutuzumab for advanced NRG1 fusion positive NSCLC and Pancreatic Cancer


  • Study

    Multi-center, open lavel study (eNRGy)
    NRG1 fusion positive NSCLC (n=64) and pancreatic adenocarcinoma (n=30) with disease progression after standard therapy



  • Efficacy

    ORR: 33% [22%-46%] in NSCLC; 40% [23% – 59%] in pancreatic cancer
    Pts with DoR > 6 mos: 43% in NSCLC, 67% in pancreatic cancer



  • Safety

    Grade >=3 AEs: Dyspnea (5%), diarrhea (5%), nausea (5%), hemorrhage (5%)



  • Zenotuzumab Label. FDA Database accessed 2024-12-06

    FDA Zenocutuzumab Product Label – BLA761352

    http://www.ncbi.nlm.nih.gov/pubmed/0

    Reviewed by Ulas D. Bayraktar, MD on Dec 6, 2024